Drug Topics April 2024

Last August, zuranolone (Zurzuvae) became the first FDA-approved pill to treat postpartum depression in adults.

The action taken by CVS staffers seems to be the only way to get the attention of corporate officials.

Digital therapeutics are positioned as front-runners in the increasingly digital future of health care.

With an unprecedented number of Americans in need of mental health care, what role should pharmacists play when it comes to screenings?

April showers might bring May flowers, but for some, the month also brings the return of allergy woes. This spring, breathe easy with these OTC allergy product recommendations.

In the United States, 12 million adults suffer from co-occurring chronic pain and anxiety or depression. Erasing stigmas, educating patients, and tailoring interventions can help to improve outcomes.

Drug Topics sat down with Sally Rafie, founder of Birth Control Pharmacist, to discuss how pharmacists are well positioned to expand access to reproductive care.

After a long hiatus, research in psychedelic medicine is progressing rapidly. With the potential approval of MDMA in the near future, what role will pharmacists play in integrating these new therapies into treatment plans?

The average US household spent $645 on OTC products in 2022.

Adults aged 65 years and older are the largest group of consumers of OTC medications.

In its ongoing campaign against “scope creep,” the American Medical Association argued that pharmacists don’t receive enough training. Physicians and pharmacists alike disagree.

The approval, awarded to Madrigal Pharmaceuticals, was based on phase 3 data demonstrating that resmetirom achieved broad treatment effects in patients with MASH with liver fibrosis.

The out-of-pocket price cap applies to all inhalers in the company’s portfolio and will launch on June 1, 2024.

Mind Medicine’s lysergide d-tartrate (MM120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in a phase 2b study.

Dexcom's Stelo will be available in summer 2024.

Pfizer's RSV vaccine received FDA approval on May 31, 2023.